Adiponectin and risk of coronary heart disease in older men and women

Jorge Kizer, Joshua I. Barzilay, Lewis H. Kuller, John S. Gottdiener

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

Context: Despite established insulin-sensitizing and antiatherogenic preclinical effects, epidemiological investigations of adiponectin have yielded conflicting findings, and its relationship with coronary heart disease (CHD) remains uncertain. Objective: Our objective was to investigate the relationship between adiponectin and CHD in older adults. Design, Setting, and Participants: This was a case-control study (n = 1386) nested within the population-based Cardiovascular Health Study from 1992-2001. Controls were frequency-matched to cases by age, sex, race, subclinical cardiovascular disease, and center. Main Outcome Measures: Incident CHD was defined as angina pectoris, percutaneous or surgical revascularization, nonfatal myocardial infarction (MI), or CHD death. A more restrictive CHD endpoint was limited to nonfatal MI and CHD death. Results: Adiponectin exhibited significant negative correlations with baseline adiposity, insulin resistance, dyslipidemia, inflammatory markers, and leptin. After controlling for matching factors, adjustment for waist to hip ratio, hypertension, smoking, alcohol, low-density lipoprotein cholesterol, creatinine, and leptin revealed a modestly increased risk of incident CHD with adiponectin concentrations at the upper end [odds ratio = 1.37 (quintile 5 vs. 1-4), 95% confidence interval 1.02-1.84]. This association was stronger when the outcome was limited to nonfatal MI and fatal CHD (odds ratio = 1.69, 95% confidence interval 1.23-2.32). The findings were not influenced by additional adjustment for weight change, health status, or cystatin C, nor were they abolished by adjustment for potential mediators. Conclusions: This study shows an association between adiponectin and increased risk of first-ever CHD in older adults. Further research is needed to elucidate the basis for the concurrent beneficial and detrimental aspects of this relationship, and under what circumstances one or the other may predominate.

Original languageEnglish (US)
Pages (from-to)3357-3364
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume93
Issue number9
DOIs
StatePublished - Sep 2008
Externally publishedYes

Fingerprint

Adiponectin
Coronary Disease
Myocardial Infarction
Leptin
Odds Ratio
Confidence Intervals
Health
Cystatin C
Insulin
Waist-Hip Ratio
Adiposity
Angina Pectoris
Dyslipidemias
LDL Cholesterol
Health Status
Insulin Resistance
Case-Control Studies
Creatinine
Cardiovascular Diseases
Smoking

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Adiponectin and risk of coronary heart disease in older men and women. / Kizer, Jorge; Barzilay, Joshua I.; Kuller, Lewis H.; Gottdiener, John S.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 93, No. 9, 09.2008, p. 3357-3364.

Research output: Contribution to journalArticle

Kizer, Jorge ; Barzilay, Joshua I. ; Kuller, Lewis H. ; Gottdiener, John S. / Adiponectin and risk of coronary heart disease in older men and women. In: Journal of Clinical Endocrinology and Metabolism. 2008 ; Vol. 93, No. 9. pp. 3357-3364.
@article{cd27710da70748b8ad5567319a39630a,
title = "Adiponectin and risk of coronary heart disease in older men and women",
abstract = "Context: Despite established insulin-sensitizing and antiatherogenic preclinical effects, epidemiological investigations of adiponectin have yielded conflicting findings, and its relationship with coronary heart disease (CHD) remains uncertain. Objective: Our objective was to investigate the relationship between adiponectin and CHD in older adults. Design, Setting, and Participants: This was a case-control study (n = 1386) nested within the population-based Cardiovascular Health Study from 1992-2001. Controls were frequency-matched to cases by age, sex, race, subclinical cardiovascular disease, and center. Main Outcome Measures: Incident CHD was defined as angina pectoris, percutaneous or surgical revascularization, nonfatal myocardial infarction (MI), or CHD death. A more restrictive CHD endpoint was limited to nonfatal MI and CHD death. Results: Adiponectin exhibited significant negative correlations with baseline adiposity, insulin resistance, dyslipidemia, inflammatory markers, and leptin. After controlling for matching factors, adjustment for waist to hip ratio, hypertension, smoking, alcohol, low-density lipoprotein cholesterol, creatinine, and leptin revealed a modestly increased risk of incident CHD with adiponectin concentrations at the upper end [odds ratio = 1.37 (quintile 5 vs. 1-4), 95{\%} confidence interval 1.02-1.84]. This association was stronger when the outcome was limited to nonfatal MI and fatal CHD (odds ratio = 1.69, 95{\%} confidence interval 1.23-2.32). The findings were not influenced by additional adjustment for weight change, health status, or cystatin C, nor were they abolished by adjustment for potential mediators. Conclusions: This study shows an association between adiponectin and increased risk of first-ever CHD in older adults. Further research is needed to elucidate the basis for the concurrent beneficial and detrimental aspects of this relationship, and under what circumstances one or the other may predominate.",
author = "Jorge Kizer and Barzilay, {Joshua I.} and Kuller, {Lewis H.} and Gottdiener, {John S.}",
year = "2008",
month = "9",
doi = "10.1210/jc.2008-0640",
language = "English (US)",
volume = "93",
pages = "3357--3364",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "9",

}

TY - JOUR

T1 - Adiponectin and risk of coronary heart disease in older men and women

AU - Kizer, Jorge

AU - Barzilay, Joshua I.

AU - Kuller, Lewis H.

AU - Gottdiener, John S.

PY - 2008/9

Y1 - 2008/9

N2 - Context: Despite established insulin-sensitizing and antiatherogenic preclinical effects, epidemiological investigations of adiponectin have yielded conflicting findings, and its relationship with coronary heart disease (CHD) remains uncertain. Objective: Our objective was to investigate the relationship between adiponectin and CHD in older adults. Design, Setting, and Participants: This was a case-control study (n = 1386) nested within the population-based Cardiovascular Health Study from 1992-2001. Controls were frequency-matched to cases by age, sex, race, subclinical cardiovascular disease, and center. Main Outcome Measures: Incident CHD was defined as angina pectoris, percutaneous or surgical revascularization, nonfatal myocardial infarction (MI), or CHD death. A more restrictive CHD endpoint was limited to nonfatal MI and CHD death. Results: Adiponectin exhibited significant negative correlations with baseline adiposity, insulin resistance, dyslipidemia, inflammatory markers, and leptin. After controlling for matching factors, adjustment for waist to hip ratio, hypertension, smoking, alcohol, low-density lipoprotein cholesterol, creatinine, and leptin revealed a modestly increased risk of incident CHD with adiponectin concentrations at the upper end [odds ratio = 1.37 (quintile 5 vs. 1-4), 95% confidence interval 1.02-1.84]. This association was stronger when the outcome was limited to nonfatal MI and fatal CHD (odds ratio = 1.69, 95% confidence interval 1.23-2.32). The findings were not influenced by additional adjustment for weight change, health status, or cystatin C, nor were they abolished by adjustment for potential mediators. Conclusions: This study shows an association between adiponectin and increased risk of first-ever CHD in older adults. Further research is needed to elucidate the basis for the concurrent beneficial and detrimental aspects of this relationship, and under what circumstances one or the other may predominate.

AB - Context: Despite established insulin-sensitizing and antiatherogenic preclinical effects, epidemiological investigations of adiponectin have yielded conflicting findings, and its relationship with coronary heart disease (CHD) remains uncertain. Objective: Our objective was to investigate the relationship between adiponectin and CHD in older adults. Design, Setting, and Participants: This was a case-control study (n = 1386) nested within the population-based Cardiovascular Health Study from 1992-2001. Controls were frequency-matched to cases by age, sex, race, subclinical cardiovascular disease, and center. Main Outcome Measures: Incident CHD was defined as angina pectoris, percutaneous or surgical revascularization, nonfatal myocardial infarction (MI), or CHD death. A more restrictive CHD endpoint was limited to nonfatal MI and CHD death. Results: Adiponectin exhibited significant negative correlations with baseline adiposity, insulin resistance, dyslipidemia, inflammatory markers, and leptin. After controlling for matching factors, adjustment for waist to hip ratio, hypertension, smoking, alcohol, low-density lipoprotein cholesterol, creatinine, and leptin revealed a modestly increased risk of incident CHD with adiponectin concentrations at the upper end [odds ratio = 1.37 (quintile 5 vs. 1-4), 95% confidence interval 1.02-1.84]. This association was stronger when the outcome was limited to nonfatal MI and fatal CHD (odds ratio = 1.69, 95% confidence interval 1.23-2.32). The findings were not influenced by additional adjustment for weight change, health status, or cystatin C, nor were they abolished by adjustment for potential mediators. Conclusions: This study shows an association between adiponectin and increased risk of first-ever CHD in older adults. Further research is needed to elucidate the basis for the concurrent beneficial and detrimental aspects of this relationship, and under what circumstances one or the other may predominate.

UR - http://www.scopus.com/inward/record.url?scp=51649108628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51649108628&partnerID=8YFLogxK

U2 - 10.1210/jc.2008-0640

DO - 10.1210/jc.2008-0640

M3 - Article

C2 - 18593765

AN - SCOPUS:51649108628

VL - 93

SP - 3357

EP - 3364

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 9

ER -